CHCHD10 (Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10) is a mitochondrial protein encoded by the CHCHD10 gene located on chromosome 22q11.23. Initially identified as a constituent of mitochondrial nucleoids, CHCHD10 has emerged as a critical player in the pathogenesis of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and spinal muscular atrophy with myopathy (SMARD1) [1].
The protein contains a unique double helix-turn-helix domain that facilitates its interaction with mitochondrial DNA (mtDNA) and various mitochondrial proteins involved in oxidative phosphorylation, mitochondrial dynamics, and cellular stress responses. Pathogenic mutations in CHCHD10 cause a spectrum of neurodegenerative phenotypes, highlighting the protein's essential role in neuronal and muscle homeostasis [2].
¶ Structure and Function
CHCHD10 is a 167-amino acid protein with a distinctive structural organization:
- N-terminal mitochondrial targeting sequence (MTS): A 20-30 amino acid cleavable presequence that directs the protein to the mitochondrial matrix
- CHCH domain: Two coiled-coil-helix motifs (CHCH1 and CHCH2) separated by a flexible linker. Each CHCH domain contains two cysteine residues that coordinate zinc ions, forming a zinc-finger-like structure essential for protein stability and DNA binding [11]
- C-terminal region: Variable sequence that mediates protein-protein interactions
The protein is imported into mitochondria via the TOM/TIM translocase system and localizes primarily to the mitochondrial matrix, where it associates with mtDNA nucleoids. CHCHD10 forms homooligomers and heterooligomers with its paralog CHCHD3 (also known as MICOS complex component MIX23) [11].
-
Mitochondrial DNA maintenance: CHCHD10 binds directly to mtDNA and regulates its replication, transcription, and packaging into nucleoids. The protein is essential for maintaining mtDNA copy number and integrity [2]
-
Oxidative phosphorylation (OXPHOS): Through its role in mtDNA maintenance, CHCHD10 indirectly supports the synthesis of OXPHOS complex components encoded by mtDNA (13 proteins). Mutations in CHCHD10 lead to reduced complex I and complex IV activity [1][2]
-
Mitochondrial dynamics: CHCHD10 interacts with OPA1 (optic atrophy 1) and other fusion machinery components to regulate mitochondrial inner membrane fusion. This function is critical for maintaining mitochondrial network integrity and distributing metabolites within neurons [10]
-
Cellular stress response: CHCHD10 localizes to stress granules under cellular stress conditions, linking mitochondrial function to RNA metabolism and proteostasis [5]
¶ Pathogenic Mutations and Disease Associations
Mutations in CHCHD10 are associated with familial and sporadic ALS, often with frontotemporal dementia features:
| Mutation |
Location |
Phenotype |
Reference |
| p.S59L |
N-terminal |
ALS/FTD with mitochondrial dysfunction |
[8] |
| p.R15P |
N-terminal |
ALS with rapid progression |
[4] |
| p.G66V |
CHCH1 domain |
FTD with motor neuron disease |
[7] |
| p.P34L |
N-terminal |
Adult-onset spinal muscular atrophy |
[9] |
| p.R98H |
CHCH2 domain |
ALS with cognitive impairment |
[1] |
The p.S59L mutation (originally identified in a large ALS/FTD pedigree) is the most extensively characterized. It causes:
- Reduced mitochondrial complex I and IV activity
- Impaired mitochondrial DNA maintenance
- Altered mitochondrial morphology (fragmented networks)
- Increased susceptibility to oxidative stress
- Deficits in autophagic clearance of damaged mitochondria
CHCHD10 mutations manifest as a continuous spectrum:
- Pure ALS: Progressive muscle weakness, fasciculations, and respiratory failure
- ALS/FTD: ALS with behavioral changes, language deficits, and executive dysfunction
- FTD with motor features: Cognitive decline with subtle motor neuron involvement
- SMARD1-like phenotype: Severe childhood-onset muscle weakness with respiratory failure
CHCHD10 mutations cause a multi-faceted mitochondrial defect:
-
Energy failure: Reduced OXPHOS capacity, particularly affecting complex I (NADH:ubiquinone oxidoreductase) and complex IV (cytochrome c oxidase). This leads to decreased ATP production and increased reliance on glycolysis [1][2]
-
mtDNA instability: Impaired replication and maintenance of mitochondrial genome, resulting in:
- Reduced mtDNA copy number
- Accumulation of deletion mutations
- Decreased expression of mtDNA-encoded proteins
-
Mitochondrial dynamics imbalance: Mutations disrupt the balance between mitochondrial fission and fusion:
- Fragmented mitochondrial networks
- Impaired mitochondrial transport along axons
- Reduced mitochondrial turnover in distal synapses
-
Calcium dysregulation: Mitochondrial calcium buffering capacity is compromised, leading to:
- Increased susceptibility to excitotoxicity
- Impaired calcium signaling in dendritic spines
- Dysregulated activation of calcium-dependent proteases
Neurons are particularly dependent on CHCHD10 function due to their high energy requirements and specialized synaptic structures:
- Axonal transport deficits: Mitochondria fail to reach distal synaptic terminals, depriving synapses of adequate energy supply
- Synaptic degeneration: Loss of mitochondria at synapses correlates with reduced synaptic vesicle density and impaired neurotransmitter release [10]
- Excitotoxicity susceptibility: Energy-depleted neurons are more vulnerable to glutamate-induced excitotoxicity, a key mechanism in ALS pathogenesis
CHCHD10 dysfunction contributes to the hallmark protein aggregates in ALS/FTD:
- TDP-43 pathology: Mitochondrial dysfunction promotes cytoplasmic TDP-43 aggregation, the most common pathology in ALS/FTD
- Stress granule formation: CHCHD10 localizes to stress granules under cellular stress, and mutations alter this process [5]
- Impaired autophagy: Defective mitochondria are not efficiently cleared, leading to accumulation of damaged organelles and protein aggregates
¶ Cellular and Animal Model Insights
Patient-derived induced pluripotent stem cells (iPSCs) and CRISPR-edited cell lines have revealed:
- Motor neuron vulnerability: Motor neurons derived from CHCHD10 mutation carriers show reduced survival and increased sensitivity to stress
- Mitochondrial fragmentation: Dynamic imaging reveals highly fragmented mitochondrial networks
- Metabolic reprogramming: Shift toward glycolytic metabolism as compensatory response to OXPHOS deficits
Transgenic mouse models expressing mutant CHCHD10 demonstrate:
- Progressive motor deficits: Age-dependent decline in rotarod performance and grip strength
- Mitochondrial pathology: Accumulation of abnormal mitochondria in motor neurons and muscle
- Motor neuron loss: Degeneration of spinal cord motor neurons with age
- Respiratory dysfunction: Diaphragm weakness and reduced respiratory capacity
- Mitochondrial antioxidants: CoQ10, MitoQ, and idebenone to combat oxidative stress
- Metabolic enhancers: Agmatine and other compounds that boost glycolytic flux
- Calcium modulators: Ameliorating excitotoxic vulnerability
- Allele-specific silencing: siRNA targeting mutant CHCHD10 transcripts while preserving wild-type function
- CRISPR correction: Base editing to correct pathogenic mutations in patient cells
- Gene replacement: AAV-mediated wild-type CHCHD10 delivery
- ALS drugs: Edaravone, riluzole (limited efficacy in CHCHD10 cases)
- FTD agents: Tau-targeting compounds under investigation
- Mitochondrial modulators: Pioglitazone and other PPAR-γ agonists
¶ Research Directions and Knowledge Gaps
- Penetrance and modifiers: Why do some CHCHD10 carriers develop ALS while others remain asymptomatic?
- Cell-type specificity: What makes motor neurons particularly vulnerable to CHCHD10 dysfunction?
- Therapeutic window: Can mitochondrial function be restored after symptoms begin?
- Biomarkers: What are the earliest markers of CHCHD10-related neurodegeneration?
- Burstein et al., CHCHD10 in neurodegeneration: a mitochondrial mystery with therapeutic implications (2023)
- He et al., CHCHD10 regulates mitochondrial DNA maintenance and oxidative phosphorylation (2021)
- Geng et al., Mutations in CHCHD10 cause mitochondrial dysfunction and ALS/FTD (2020)
- Wong et al., CHCHD10 mutations impair mitochondrial dynamics and synapse function in neurons (2023)
- Cheng et al., CHCHD10 regulates stress granule formation in ALS (2022)
- Andersen et al., Genetic landscape of CHCHD10 in ALS and FTD (2024)
- Yang et al., Mitochondrial CHCHD10 is essential for synaptic function (2021)
- Bailey et al., CHCHD10p.S59L causes motor neuron disease with mitochondrial dysfunction (2019)
- Maremonti et al., CHCHD10 variants in FTD and ALS: functional characterization (2019)
- Sheng et al., CHCHD10 regulates OPA1-mediated mitochondrial fusion (2019)
- Romani et al., CHCHD10 is a mitochondrial nucleoid protein (2013)
- Liu et al., CHCHD10 in cellular stress response and protein aggregation (2022)